GENFIT S.A. (GNFT): Price and Financial Metrics


GENFIT S.A. (GNFT): $4.50

0.09 (+2.04%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add GNFT to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

GNFT POWR Grades

  • GNFT scores best on the Value dimension, with a Value rank ahead of 95.51% of US stocks.
  • GNFT's strongest trending metric is Growth; it's been moving down over the last 56 days.
  • GNFT's current lowest rank is in the Momentum metric (where it is better than 4.66% of US stocks).

GNFT Stock Summary

  • With a price/earnings ratio of 3.18, GENFIT SA P/E ratio is greater than that of about just 4.28% of stocks in our set with positive earnings.
  • With a year-over-year growth in debt of -66.23%, GENFIT SA's debt growth rate surpasses just 3.59% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, GENFIT SA is reporting a growth rate of -215.94%; that's higher than just 7.25% of US stocks.
  • Stocks that are quantitatively similar to GNFT, based on their financial statements, market capitalization, and price volatility, are NVEC, IMOS, IKT, HCM, and ERYP.
  • GNFT's SEC filings can be seen here. And to visit GENFIT SA's official web site, go to www.genfit.com.

GNFT Stock Price Chart Interactive Chart >

Price chart for GNFT

GNFT Price/Volume Stats

Current price $4.50 52-week high $5.05
Prev. close $4.41 52-week low $3.02
Day low $4.28 Volume 9,380
Day high $4.52 Avg. volume 9,673
50-day MA $3.97 Dividend yield N/A
200-day MA $3.92 Market Cap 224.26M

GENFIT S.A. (GNFT) Company Bio


Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné and Bart Staels on September 1999 and is headquartered in Loos, France.


GNFT Latest News Stream


Event/Time News Detail
Loading, please wait...

GNFT Latest Social Stream


Loading social stream, please wait...

View Full GNFT Social Stream

Latest GNFT News From Around the Web

Below are the latest news stories about GENFIT SA that investors may wish to consider to help them evaluate GNFT as an investment opportunity.

GENFIT Announces 2023 Financial Calendar

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 24, 2023 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs, today announced its provisional financial calendar for 2023. 2023 Financial Calendar February 28, 2023 Publication of revenue and cash position at December 31, 2022 April 13, 2023 Publication of Full Year 2022 financial

Yahoo | January 24, 2023

GENFIT to Participate in Upcoming Investor Conferences

Lille (France ), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 5 , 202 3 – GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs, today announced that management will participate in upcoming investor conferences.

GlobeNewswire | January 5, 2023

A Long Wait For Genfit May Be Worth It

Elafibranor is Genfit''s only potential revenue generator in the next 4 years. See why investors should be prudent with GNFT stock.

Seeking Alpha | November 23, 2022

GENFIT Pipeline Day Highlights Diverse Product Portfolio in Underserved Liver Diseases

Phase 3 data for elafibranor in primary biliary cholangitis (PBC) expected in 2Q23Expanded pipeline now covers five therapeutic areas with high unmet medical need via six independent programs exploring the potential of differentiated mechanisms of actionA regular stream of new clinical data expected over the next few years across the spectrum of development stages (Phase 1, Phase 2, Phase 3)Aggregated global market size potential >$15bn1, distributed among acute on-chronic liver failure (ACLF) w

Yahoo | November 17, 2022

GENFIT Reports Third Quarter 2022 Financial Information

Lille, France; Cambridge, MA; November 10, 2022 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced its cash position as of September 30, 2022 and revenue for the first nine months of 2022 1 .

GlobeNewswire | November 10, 2022

Read More 'GNFT' Stories Here

GNFT Price Returns

1-mo 5.88%
3-mo 16.28%
6-mo -3.02%
1-year 8.96%
3-year -74.32%
5-year N/A
YTD 2.53%
2022 -12.22%
2021 4.17%
2020 -75.88%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6509 seconds.